This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Selective serotonin reuptake inhibitors have been associated with the risk of restless legs syndrome (RLS), suggesting that dysregulation of serotonergic neurotransmission may provoke or exacerbate RLS.
Methods: We compared the availability of serotonin transporter (SERT) between 16 drug-naïve patients with RLS and 16 healthy controls. SERT was measured in the pons and medulla via [123I]-2β-carbomethoxy-3β-(4-iodophenyl) tropane (β-CIT) SPECT. A ratio of specific to nonspecific brain uptake (V3″) was used for all comparisons. RLS was diagnosed according to the criteria proposed by the National Institute of Health, and its severity was measured using the International RLS Study Group (IRLSSG) Severity Scale.
Results: The availability of SERT was similar in the RLS group and the control group with regards to the pons (1.24 ± 0.31 vs 1.24 ± 0.25, p > 0.1) and the medulla (0.99 ± 0.25 vs 1.00 ± 0.23, p > 0.1). However, IRLSSG Severity Scale scores increased with decrease of SERT availability in both the pons (β = −0.50, t = −3.19, p = 0.009) and the medulla (β = −0.42, t = −2.44, p = 0.03).
Conclusions: Although serotonin transporter (SERT) availability in pons and medulla was similar in the restless legs syndrome (RLS) group and the control group, the severity of RLS symptoms increased as the availability of SERT decreased. These data partially support the hypothesis that an increase of serotonergic neurotransmission in the brainstem may exacerbate RLS, possibly via dual modulations on striatal dopaminergic neurotransmission and on the activities of spinal motor and sensory neurons.
Glossary
- CERAD=
- Consortium to Establish a Registry for Alzheimer's Disease;
- DSM-IV=
- Diagnostic and Statistical Manual of Mental Disorders, 4th edition;
- GDS=
- Geriatric Depression Scale;
- IRLSSG=
- International RLS Study Group;
- MINI=
- Mini International Neuropsychiatric Interview;
- RLS=
- restless legs syndrome;
- ROI=
- region of interest;
- SERT=
- serotonin transporter;
- SNRI=
- serotonin-norepinephrine reuptake inhibitor;
- SSRI=
- selective serotonin reuptake inhibitor.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Topics Discussed
Alert Me
Recommended articles
Association between restless legs syndrome and other movement disorders
Characteristics and determinants of restless legs syndrome in pregnancy
Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease)
Reduced bone resorption and increased bone mineral density in women with restless legs syndrome